Clinical Pharmacokinetics of Ombitasvir
Author:
Funder
AbbVie
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Link
http://link.springer.com/article/10.1007/s40262-017-0518-4/fulltext.html
Reference29 articles.
1. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015;59(2):979–87.
2. Menon RM, Polepally AR, Khatri A, Awni WM, Dutta S. Clinical pharmacokinetics of paritaprevir. Clin Pharmacokinet. 2017. doi: 10.1007/s40262-017-0520-x .
3. King JR, Zha J, Khatri A, Dutta S, Menon RM. Clinical pharmacokinetics of dasabuvir. Clin Pharmacokinet. 2017. doi: 10.1007/s40262-017-0519-3 .
4. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370(3):222–32.
5. Viekirax. Summary of product characteristics. UK: AbbVie Ltd; 2015.
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication;Antiviral Research;2024-05
2. A Synopsis of Hepatitis C Virus Treatments and Future Perspectives;Current Issues in Molecular Biology;2023-10-11
3. HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments;Topics in Medicinal Chemistry;2019
4. Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients;European Journal of Drug Metabolism and Pharmacokinetics;2018-06-16
5. Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling;Journal of Medical Virology;2018-03-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3